The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Mortality results from a randomized prostate-cancer screening trial.
Screening and prostate-cancer mortality in a randomized European study. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015. Improvements in inter-reader agreement, development of computer-aided diagnostic systems and assessment of biomarkers to use in combination with mpMRI are needed.įitzmaurice, C. In men with negative mpMRI, omitting a biopsy can only be considered when the clinical suspicion of prostate cancer is low. The use of mpMRI as a triage test is still controversial. The use of mpMRI is considered useful the use of mpMRI-targeted biopsy is increasing the detection of clinically significant prostate cancer in both biopsy-naive and previous negative biopsy settings. Interpretation and reporting of mpMRI must be carried out following standardized scoring systems (such as Prostate Imaging Reporting and Data System (PI-RADS) v2). MpMRI should include four sequences: T1-weighted images, T2-weighted images, diffusion-weighted images (DWI) and dynamic contrast-enhanced imaging (DCEI). Multiparametric MRI (mpMRI) of the prostate is a novel promising tool for diagnosis of prostate cancer that might help to reduce overdiagnosis of insignificant prostate cancer.
0 kommentar(er)
